Form 4: Passage Bio Director Kapadia Receives Stock Options

Sandip Kapadia, a director at Passage Bio, Inc., was granted stock options to purchase 47,693 shares of common stock at an exercise price of $1.28 on May 21, 2024.

Summary

• On May 21, 2024, Sandip Kapadia, a director of Passage Bio, Inc. (PASG), was granted stock options.
• The options allow Kapadia to purchase 47,693 shares of Passage Bio's common stock at an exercise price of $1.28 per share.
• The stock options vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
• The options expire on May 21, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard transaction (granting of stock options) with no explicit positive or negative implications.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's value.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
• The size of the grant (47,693 shares) would need to be compared to similar grants at peer companies of comparable market capitalization and stage of development to assess its relative value.
• Companies like BioMarin Pharmaceutical Inc. and Sarepta Therapeutics, Inc. also use stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant could potentially benefit shareholders if it incentivizes the director to improve company performance.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates